AzTrials
AzTrials

Obsessive Compulsive DisorderNCT02196090

Application of Vagal Stimulation in Exposure and Response Prevention for Obsessive Compulsive Disorder

A study testing Exposure and Response Prevention and Cold face gel mask in people with Obsessive Compulsive Disorder, run by King's College London at 1 site in United Kingdom.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Obsessive Compulsive Disorder (OCD) is a condition associated with recurrent intrusive distressing thoughts, images and urges compelling the person to perform neutralizing acts or thoughts to the extent of significantly interfering with their daily activities. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Obsessive Compulsive Disorder
What is being tested?
Exposure and Response Prevention and Cold face gel mask
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited Kingdom
Study dates
Jul 2014to Feb 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • age over 18 years
  • signed informed consent
  • established diagnosis of OCD

Who cannot join

  • patients who do not understand English sufficiently to complete the questionnaires
  • patients who do not have mental capacity to provide informed consent

Trial locations and contacts

1 site in 1 country.

Roman Duncko, PhD MRCPsych contact

+44(0)2032284545

roman.duncko@slam.nhs.uk

United Kingdom1 site, 1 recruiting
  • Anxiety Disorders Residential Unit, Bethlem Royal Hospital

    Beckenham, Kent, BR3 3BX

    Roman Duncko, PhD MRCPsych, +44(0)2032284545, roman.duncko@slam.nhs.uk

    Recruiting

Other trials in United Kingdom

About this study

Official title: Application of Vagal Stimulation by Cold Face Mask in Exposure and Response Prevention for Obsessive Compulsive Disorder

Obsessive Compulsive Disorder (OCD) is a condition associated with recurrent intrusive distressing thoughts, images and urges compelling the person to perform neutralizing acts or thoughts to the extent of significantly interfering with their daily activities. The symptoms of OCD are associated with both subjective and objective signs of distress. Treatment for Obsessive Compulsive Disorder is often associated with significant subjective distress with high dropout rates and often only limited improvement. Attempts to reduce distress in anxiety often focus on re-establishing the sympathovagal balance by enhancing the vagal or parasympathetic tone and it has been suggested that this can reduce the mobilization behaviours of fight or flight response and improve emotion regulation. This study will investigate the effect of a procedure potentially reducing distress and improving outcome of treatment in inpatients admitted for treatment for OCD to the Anxiety Disorders Residential Unit. The procedure will be based on increasing vagal tone by application of cold face mask on 3 consecutive days in addition to the standard Exposure and Response Prevention therapy (ERP).

Read the detailed description
  1. Background Obsessive Compulsive Disorder (OCD) is a condition associated with recurrent intrusive distressing thoughts, images and urges compelling the person to perform neutralizing acts or thoughts to the extent of significantly interfering with their daily activities. The symptoms of OCD are associated with both subjective and objective signs of distress. Psychophysiological studies of OCD and other anxiety disorders often report abnormal sympathovagal balance with decreased parasympathetic or vagal tone and increased sympathetic tone (Hoehn-Saric et al 1995, Broderick et al 2013, Kawano et al 2012, Pittig et al 2013, Buhlmann et al 2007, Blechert et al 2007, Friedman and Thayer 1998). The first line treatment of OCD is Cognitive Behaviour Therapy (CBT) which includes Exposure and Response Prevention (ERP) when the patient tests out their fears without responding by compulsive act (NICE Clinical Guideline 31). ERP treatment itself is often associated with significant subjective distress (Kellner et al 2012) with dropout rates up to 20% and only minimal improvement in another 20% of patients (Foa 2010). Various modalities of treatment reducing the subjective and physiological distress have been used in treatment of anxiety disorders and symptoms (Streeter et al 2012, Miu et al 2009, Gorman et al 2000) and similar approach could increase the rates of improvement and adherence to ERP treatment in OCD. Most of the attempts to reduce distress in anxiety focus on re-establishing the sympathovagal balance by enhancing the vagal or parasympathetic tone and it has been suggested that this can reduce the mobilization behaviours of fight or flight response and improve emotion regulation (Austin et al 2007). Disgust is an emotion implicated to have significant role on anxiety disorders such as OCD with contamination fears (Moretz and McKay 2008). It has been shown to have only limited response to exposure therapy (Olatunji et al 2009) and can be associated with increased avoidance and reduced compliance with exposures (Olatunji et al 2007) possibly contributing to poorer treatment outcome. Disgust can be associated with changes in sympathovagal balance (Ottaviani et al 2013) but the effect of manoeuvres affecting this balance has not been tested. Vagal tonus can be increased with specific procedures called vagal manoeuvres. These include the diving reflex, Valsalva manoeuvre, pressure on the eyeball and carotid sinus massage, with the diving reflex being one of the most effective (Arnold 1999). The diving reflex is a phylogenetically ancient physiological phenomenon believed to facilitate survival after immersion in cold water through bradycardia and peripheral vasoconstriction redistributing blood flow to vital organs (Gooden 1994). The combined bradycardia and vasoconstriction effect indicates on complex sympathovagal activation and the bradycardia itself is believed to be due to central vagal activation (Stemper et al 2002). The natural trigger for diving reflex includes change in body position, apnoea and sensation of cold and wet surface on the face and a cold sensation on the face is sufficient to induce the vagal response. This is believed to be transmitted by the ophthalmic branch of the trigeminal nerve and can be achieved by using cold compressions or cold face gel masks (Khurana et al. 1980). The physiological response during diving reflex can be measured by recording standard physiological measures such as heart rate, blood pressure or skin conductance. Heart rate and its interpretation in terms of heart rate variability is becoming more frequently utilized to evaluate the balance between sympathetic and parasympathetic nervous system. Most frequently used is the frequency domain approach which allows differentiating specific frequency bands. The low frequency (LF) band groups the variability between 0.05-0.15Hz and is believed to represent the sympathetic cardiac control with slower unmyelinated nerve fibres while the high frequency (HF) band including frequencies between 0.15-0.4Hz reflects the parasympathetic or vagal control with faster myelinated nerve fibres (Berntson et al 1997).
  2. Aims of the study

The aim of the study is to evaluate the effect of a simple vagal manoeuvre, that is a cold face gel mask application, on subjective measures of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in Theory A/B and an increase in Feeling of being supported, Readiness to face the fear during the ERP treatment of OCD by using a single-case series experimental design and to explore the relationship between subjective measures and sympathovagal balance measured by heart rate variability. Our hypothesis is that:

  1. ERP with application of cold gel face mask (Condition B) will be associated with faster reduction of visual analogue scales of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in Theory A/B and an increase in Feeling of being supported, Readiness to face the fear compared to ERP as usual with simply resisting the compulsive behaviour (Condition C).
  2. Increase in vagal tonus as documented by heart rate variability measures will correlate with the effect on visual analogue scales of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in Theory A/B, Feeling of being supported and Readiness to face the fear.
  3. Methods
  4. Participants: Participants will be recruited from the Anxiety Disorders Residential Unit (ADRU), Bethlem Royal Hospital. All patients admitted to ADRU have the opportunity to consent to be contacted about participating in research studies. Only patients admitted to ADRU for treatment of OCD who provided such initial consent will be approached by Dr Roman Duncko regarding the written informed consent to participate in the present study. ii. Procedure and Design: On each day of the study, therapy will begin with the Baseline phase (Condition A) and record the psychological (visual analogue scales of Anxiety, Disgust, Belief in obsession, Strength of urge for compulsion, Strength of belief in Theory A/B, Feeling of being supported, Readiness to face the fear) and physiological measures (HR recording) on 3-5 consecutive 5min intervals or until stable baseline measures are achieved. After that, the participant will proceed with the Intervention phase by applying ERP with the use of triggers as identified on their individual hierarchy. Each ERP session will follow the same structure by first obtaining the session baseline at 3 time points, then exposure to trigger and continue with preventing the response while applying the cold face mask for 5 minutes (Condition B) or without using the face mask (Condition C). Psychological and physiological measures will be obtained in 5 minute intervals until return to session baseline. ERP sessions will follow in alternating order for 4 sessions per day (Day 1: ABCBC, Day 2: ACBCB, Day 3: ABCBC). All baseline and exposure measures will be recorded by the investigator who will by accompanying the participant during the procedure. Cold face gel masks will be stored in refrigerator at the ADRU and will be available to the participant as required. iii. Psychological measures: Visual analogue scales for measurement of severity of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in theory A/B, Strength of belief in Theory A/B, Feeling of being supported, Readiness to face the fear will be used by the participant at time points as specified above. In addition to this the participant will be assessed for their clinical symptoms (YBOCS, OCI) on weekly basis as part of their standard treatment plan.

On the last day of the study, participants will be asked to complete the Client Satisfaction Questionnaire based on (Larsen et al 1979) to explore the feasibility and acceptability of the cold face gel mask application during ERP.

iv. Physiological measures: Heart rate variability analysis will be performed on data recorded with a Polar RS800CX heart rate monitor using a H2 chest sensor. Polar monitors have been tested against standard clinical ECG equipment and found to be suitable for heart rate variability analysis (Vanderlei et al 2008). In the morning of the study day, the participants will place the Polar heart rate sensor on their chest using the elastic strap. They will be instructed how to use the heart rate monitor watch Polar RS800CX to record the heart rate and press the mark recording button at specific times during each procedure. At the end of each study day, the data will be downloaded from the heart rate monitor watch and 3 time intervals of 2 minutes will be identified: at the beginning of the condition - time 0, at the beginning of the procedure - time 15, at the end of the condition - time 45. Time intervals will be screened for artefacts and used for heart rate variability analysis using standalone analysis software (Niskanen et al 2004). Variables selected for analysis will include heart rate per minute, time domain measures (RMSSD, NN50) and frequency domain measures (nLF at 0.05-0.15Hz, nHF at 0.15-0.04Hz, LF/HF).

  1. Data analysis: Data will be initially evaluated by visual inspection for each participant individually. After that, values obtained for a specific time interval and phase will be averaged among all participants and again evaluated by visual inspection. Percentage of non-overlapping data analysis will be performed to detect statistically significant change between the baseline and intervention phase. Pearson's correlation will be used for correlation analyses.
  2. Project timetable

The project is planned to run for 6-12 months depending on the rate of recruitment of participants.

  1. Expertise in team

Dr David Veale is a consultant psychiatrist in Cognitive Behaviour Therapy at the South London and Maudsley Trust and a Honorary Senior Lecturer at the Institute of Psychiatry, Kings College London. Specialisms include obsessive compulsive disorder.

Dr Roman Duncko, PhD is a ST5 trainee in General Adult Psychiatry at the South London and Maudsley Trust with long-term research interest in anxiety disorders and autonomic nervous system function.

  1. Ethical considerations

All ethical considerations are outlined in the Participant Information and Consent Form that will be distributed to participants. All patients admitted to ARDU who fulfil the inclusion criteria will be approached about participating in the study. All participants will require signing an informed consent to participate. All information and data obtained during the study will be kept in strict confidence. Upon recruitment, every participant will be assigned an anonymous code and the lists linking the code with personal identifying information will be kept secure and separate from the data. Only the Principal Investigator and researchers authorized by the PI will have access to the identifying lists. Every participant will undergo the same procedures with slightly variable order. No deception will be used and participants will be informed as to exactly what the study is about. All participants will be informed at the time of providing consent to participate that they can withdraw from the study at any time and that this will not affect the care they will receive.

  1. Dissemination and implementation

Results of the study will be used for poster and/or oral presentations at suitable conferences and for preparing a manuscript for submission in a scientific journal. Depending on the outcome of the study further research will be planned to evaluate the effect of cold face gel mask in a study with randomized control trial design.

Being tested
Exposure and Response Prevention, Cold face gel mask
Keywords
OCD, Exposure and Response Prevention, Vagal Stimulation
Medical subject headings
Obsessive-Compulsive Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Exposure and Response PreventionBehavioural

    Also called ERP

    A procedure where patients with OCD test out their fears without responding by compulsive act.

  • Cold face gel maskDevice

    Temporary application of cold eye mask on the face is commonly used for relaxation purpose.

Study groups in NCT02196090
Study groupRoleWhat they receive
Single armExperimentalStudy uses the single case series design with only one arm. All participants in the one arm will have procedures with treatment as usual (Exposure and Response Prevention) alternating with procedures including the vagal maneuver (Cold Face Gel Mask).
Receives: Behavioral: Exposure and Response Prevention; Device: Cold face gel mask

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Visual analogue scales at baseline

    Rates of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in theory A/B, Strength of belief in Theory A/B, Feeling of being supported, Readiness to face the fear obtained from visual analogue scales.

    Measured: This measure will be assessed with every exposure on each day of the study at baseline - 5 minutes prior to exposure.

  2. Visual analogue scales at exposure

    Rates of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in theory A/B, Strength of belief in Theory A/B, Feeling of being supported, Readiness to face the fear obtained from visual analogue scales.

    Measured: This measure will be assessed with every exposure on each day of the study immediately after finishing the exposure

  3. Visual analogue scales 5 minutes post exposure

    Rates of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in theory A/B, Strength of belief in Theory A/B, Feeling of being supported, Readiness to face the fear obtained from visual analogue scales.

    Measured: This measure will be assessed with every exposure on each day of the study at 5 minutes after the exposure.

  4. Visual analogue scales 10 minutes post exposure

    Rates of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in theory A/B, Strength of belief in Theory A/B, Feeling of being supported, Readiness to face the fear obtained from visual analogue scales.

    Measured: This measure will be assessed with every exposure on each day of the study at 10 minutes after the exposure.

  5. Visual analogue scales 15 minutes post exposure

    Rates of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in theory A/B, Strength of belief in Theory A/B, Feeling of being supported, Readiness to face the fear obtained from visual analogue scales.

    Measured: This measure will be assessed with every exposure on each day of the study at 15 minutes after the exposure.

Secondary outcomes (1)
  1. Heart rate variability measures

    Heart rate will be recorded during each ERP session. Hear rate and Heart Rate Variability (HRV) measures will be analyzed in 2 minute intervals corresponding with the timepoints of filling in the VAS at baseline, during the exposure and at three time points after the exposure, at 5, 10 and 15 minutes after the exposure. The Heart Rate Variability measures will include heart rate per minute, time domain measures (RMSSD, NN50) and frequency domain measures (nLF at 0.05-0.15Hz, nHF at 0.15-0.04Hz, LF/HF).

    Measured: Heart rate variability measures will be analyzed for specific timeintervals at baseline, during exposure and at three time points after the exposure, at 5, 10 and 15 minutes after exposure.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jul 2014 (estimated)
  2. Study startJul 2014
  3. Primary completionFeb 2016 (estimated)
  4. Study completionFeb 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02196090
Sponsor's protocol ID
SLAM-RD-001
Status last verified
Feb 2016
First submitted
24 Jun 2014
Last updated
29 Feb 2016
Results posted
No
Data monitoring committee
No

Publications

  • Arnold RW. The human heart rate response profiles to five vagal maneuvers. Yale J Biol Med. 1999 Jul-Aug;72(4):237-44.

    PubMed 10907774
  • Austin MA, Riniolo TC, Porges SW. Borderline personality disorder and emotion regulation: insights from the Polyvagal Theory. Brain Cogn. 2007 Oct;65(1):69-76. doi: 10.1016/j.bandc.2006.05.007. Epub 2007 Jul 30.

    PubMed 17659821
  • Berntson GG, Bigger JT Jr, Eckberg DL, Grossman P, Kaufmann PG, Malik M, Nagaraja HN, Porges SW, Saul JP, Stone PH, van der Molen MW. Heart rate variability: origins, methods, and interpretive caveats. Psychophysiology. 1997 Nov;34(6):623-48. doi: 10.1111/j.1469-8986.1997.tb02140.x.

    PubMed 9401419
  • Blechert J, Michael T, Grossman P, Lajtman M, Wilhelm FH. Autonomic and respiratory characteristics of posttraumatic stress disorder and panic disorder. Psychosom Med. 2007 Dec;69(9):935-43. doi: 10.1097/PSY.0b013e31815a8f6b. Epub 2007 Nov 8.

    PubMed 17991823
  • Broderick J, Grisham JR, Weidemann G. Disgust and fear responding in contamination-based obsessive-compulsive disorder during pictorial exposure. Behav Ther. 2013 Mar;44(1):27-38. doi: 10.1016/j.beth.2012.05.005. Epub 2012 Jun 8.

    PubMed 23312424
  • Buhlmann U, Wilhelm S, Deckersbach T, Rauch SL, Pitman RK, Orr SP. Physiologic responses to loud tones in individuals with obsessive-compulsive disorder. Psychosom Med. 2007 Feb-Mar;69(2):166-72. doi: 10.1097/PSY.0b013e31802f2799. Epub 2007 Feb 8.

    PubMed 17289827
  • Foa EB. Cognitive behavioral therapy of obsessive-compulsive disorder. Dialogues Clin Neurosci. 2010;12(2):199-207. doi: 10.31887/DCNS.2010.12.2/efoa.

    PubMed 20623924
  • Friedman BH, Thayer JF. Anxiety and autonomic flexibility: a cardiovascular approach. Biol Psychol. 1998 Nov;49(3):303-23. doi: 10.1016/s0301-0511(98)00051-9.

    PubMed 9858059
  • Gooden BA. Mechanism of the human diving response. Integr Physiol Behav Sci. 1994 Jan-Mar;29(1):6-16. doi: 10.1007/BF02691277.

    PubMed 8018553
  • Gorman JM, Sloan RP. Heart rate variability in depressive and anxiety disorders. Am Heart J. 2000 Oct;140(4 Suppl):77-83. doi: 10.1067/mhj.2000.109981.

    PubMed 11011352
  • Hoehn-Saric R, McLeod DR, Hipsley P. Is hyperarousal essential to obsessive-compulsive disorder? Diminished physiologic flexibility, but not hyperarousal, characterizes patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995 Aug;52(8):688-93. doi: 10.1001/archpsyc.1995.03950200078017.

    PubMed 7632122
  • Kawano A, Tanaka Y, Ishitobi Y, Maruyama Y, Ando T, Inoue A, Okamoto S, Imanaga J, Kanehisa M, Higuma H, Ninomiya T, Tsuru J, Akiyoshi J. Salivary alpha-amylase and cortisol responsiveness following electrical stimulation stress in obsessive-compulsive disorder patients. Psychiatry Res. 2013 Aug 30;209(1):85-90. doi: 10.1016/j.psychres.2012.11.010. Epub 2012 Dec 23.

    PubMed 23266021
  • Kellner M, Wiedemann K, Yassouridis A, Muhtz C. Non-response of cortisol during stressful exposure therapy in patients with obsessive-compulsive disorder--preliminary results. Psychiatry Res. 2012 Sep 30;199(2):111-4. doi: 10.1016/j.psychres.2012.04.029. Epub 2012 May 11.

    PubMed 22578822
  • Khurana RK, Watabiki S, Hebel JR, Toro R, Nelson E. Cold face test in the assessment of trigeminal-brainstem-vagal function in humans. Ann Neurol. 1980 Feb;7(2):144-9. doi: 10.1002/ana.410070209.

    PubMed 7369721
  • Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann. 1979;2(3):197-207. doi: 10.1016/0149-7189(79)90094-6. No abstract available.

    PubMed 10245370

Questions about this trial

What is this clinical trial studying?

A study testing Exposure and Response Prevention and Cold face gel mask in people with Obsessive Compulsive Disorder, run by King's College London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Roman Duncko, PhD MRCPsych (+44(0)2032284545, roman.duncko@slam.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Visual analogue scales at baseline (time frame: This measure will be assessed with every exposure on each day of the study at baseline - 5 minutes prior to exposure.). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02196090, which also lists 25 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Feb 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in